1 Min Read
Dec 30 (Reuters) - OPKO Health Inc said on Friday its experimental drug for growth hormone deficiency did not provide a statistically significant benefit over a placebo in a late-stage study.
The drug, hGH-CTP, is being developed in collaboration with Pfizer Inc.
Growth hormone deficiency is a rare disorder characterized by the inadequate secretion of the growth hormone.
Reporting by Divya Grover in Bengaluru